Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

This study found that bikunin is expressed in human keratinocytes and may play a role in regulating keratinocyte function during mitosis or inflammation.

In this randomized controlled trial, researchers found that after six months of treatment, oral baricitinib was significantly more effective than methotrexate for improving hair regrowth in patients with severe alopecia areata, as measured by the Severity of Alopecia Tool score.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

In this report, a 25-year-old female patient with anti-MDA5 antibody-positive dermatomyositis and alopecia areata achieved complete remission of hair loss after treatment with baricitinib.

This study found that administering botulinum toxin A via Flex-PADs to mouse footpads inhibited sweating similarly to traditional injections, suggesting a promising patient-friendly delivery method for hyperhidrosis treatment.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

This commentary discusses how microphthalmic-associated transcription factor levels in circulating tumor cells correlate with melanoma progression and suggests the factor may be up-regulated in vivo, but it reports no new clinical results.

This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.

This study observed that a hair tonic containing 3% ethanolic extract of bidara leaves stimulated rabbit hair growth more effectively over 28 days than both distilled water and 2% minoxidil, attributing this effect to the extract's anti-inflammatory and antioxidant properties.

Tofacitinib might be used to treat hair loss.

This study found that A(3)B(5) downregulates melanin production and suppresses melanoma cell growth by promoting proteasomal degradation of TRP-2.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

In this report, a 58-year-old woman with ocular myasthenia gravis experienced complete resolution of symptoms and hair regrowth after six months of treatment with the JAK inhibitor baricitinib, highlighting a potential new therapeutic approach for this condition.

This study found that methyl jasmonate can induce tanshinone biosynthesis in S. miltiorrhiza by affecting the expression of the SmMEC gene, as supported by RT-PCR and transcriptomic data.

This study found that TPA was significantly more effective than mezerein in inducing dark basal keratinocytes in mouse skin, which may be important in early tumor promotion stages.

This system overview describes the UTokyo Repository's role in storing and providing online access to digital resources from the University of Tokyo, reporting no new empirical findings or research results.

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

This study found that the Arabidopsis thaliana protein Formin 2 localizes to plasmodesmata and is crucial for regulating their permeability by anchoring actin filaments, which affects virus susceptibility.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

This review discusses the role of matriptase and its inhibitor HAI-1 in epithelial homeostasis and cancer development, highlighting their imbalance's link to cancer progression without presenting new experimental results.

In this study, a case of a patient with dermatomyositis and alopecia universalis showed successful treatment with tofacitinib, suggesting potential responsiveness to janus kinase inhibitors.

This project developed an SMS-based e-voting application using Gammu and PHP, aiming to facilitate an accurate, quick, and transparent voting process for student elections.

This paper discusses radiation exposure management following the Fukushima nuclear disaster, emphasizing stable iodine prophylaxis for high-risk populations and the need for public education, without presenting new clinical findings.

This study found that dihydrotestosterone induces hair loss in male C57BL/6 mice, and this effect can be partially reversed by the androgen receptor antagonist bicalutamide.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.